Mannkind: HC Wainwright Raises PT to $11, Maintains Buy Rating

Mannkind: HC Wainwright Raises PT to $11, Maintains Buy Rating

September 02, 2025

In a significant update to its investment recommendation, H.C. Wainwright & Co. has raised its price target for MannKind Corporation (NASDAQ: MNKD) to $11, while maintaining a Buy rating on the biopharmaceutical company. The firm's latest research note highlights MannKind's strategic acquisition of scPharmaceuticals, which the analysts believe will benefit the company's revenue base and overall financial prospects [1].

MannKind Corporation specializes in developing and commercializing innovative therapeutic devices and products for endocrine and orphan lung diseases. The company's pipeline includes products such as Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, and several others in various stages of development [1].

The acquisition of scPharmaceuticals is seen as a strategic move by MannKind, as it aligns with the company's focus on diversifying its revenue streams. H.C. Wainwright & Co. has praised the acquisition, describing it as a "very reasonable" deal that aligns well with MannKind's long-term growth strategy [1].

While MannKind offers potential for investors, H.C. Wainwright & Co. acknowledges that certain AI stocks may offer greater upside potential and carry less downside risk. However, the firm's positive outlook on MannKind's prospects, particularly in light of the acquisition, suggests that the company remains a solid long-term investment [1].

As of the latest update, MannKind's stock price has been volatile, reflecting the broader market conditions and the ongoing development of its pipeline. The company's ability to execute on its strategic initiatives and the success of its product portfolio will be key factors in determining its future performance.

References:
[1] https://finance.yahoo.com/news/h-c-wainwright-reiterates-buy-041657568.html